Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System

Type 2 diabetes mellitus (T2DM) is marked by chronic hyperglycemia, gradually worsening β-cell failure, and insulin resistance. Glucotoxicity and oxidative stress cause β-cell failure by increasing reactive oxygen species (ROS) production, impairing insulin secretion, and disrupting transcription fa...

Full description

Saved in:
Bibliographic Details
Main Authors: Il Rae Park, Yong Geun Chung, Kyu Chang Won
Format: Article
Language:English
Published: Korean Diabetes Association 2025-01-01
Series:Diabetes & Metabolism Journal
Subjects:
Online Access:http://e-dmj.org/upload/pdf/dmj-2024-0796.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850097020667166720
author Il Rae Park
Yong Geun Chung
Kyu Chang Won
author_facet Il Rae Park
Yong Geun Chung
Kyu Chang Won
author_sort Il Rae Park
collection DOAJ
description Type 2 diabetes mellitus (T2DM) is marked by chronic hyperglycemia, gradually worsening β-cell failure, and insulin resistance. Glucotoxicity and oxidative stress cause β-cell failure by increasing reactive oxygen species (ROS) production, impairing insulin secretion, and disrupting transcription factors such as pancreatic and duodenal homeobox 1 (PDX-1) and musculoaponeurotic fibrosarcoma oncogene family A (MafA). Cluster determinant 36 (CD36), an essential glycoprotein responsible for fatty acid uptake, exacerbates oxidative stress and induces the apoptosis of β-cells under hyperglycemic conditions through pathways involving ceramide, thioredoxin-interacting protein (TXNIP), and Rac1-nicotinamide adenine dinucleotide phosphate oxidase (NOX)-mediated redoxosome formation. Targeting CD36 pathways has emerged as a promising therapeutic strategy. Oral hypoglycemic agents, such as metformin, teneligliptin, and pioglitazone, have shown protective effects on β-cells by enhancing antioxidant defenses. These agents reduce glucotoxicity via mechanisms such as suppressing CD36 expression and stabilizing mitochondrial function. Additionally, novel insights into the glutathione antioxidant system and its role in β-cell survival underscore its therapeutic potential. This review focuses on the key contribution of oxidative stress and CD36 to β-cell impairment, the therapeutic promise of antioxidants, and the need for further research to apply these findings in clinical practice. Promising strategies targeting these mechanisms may help preserve β-cell function and slow T2DM progression.
format Article
id doaj-art-a52881d6972c42d4b604cd1cf37843de
institution DOAJ
issn 2233-6079
2233-6087
language English
publishDate 2025-01-01
publisher Korean Diabetes Association
record_format Article
series Diabetes & Metabolism Journal
spelling doaj-art-a52881d6972c42d4b604cd1cf37843de2025-08-20T02:41:07ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872025-01-0149111210.4093/dmj.2024.07962906Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant SystemIl Rae Park0Yong Geun Chung1Kyu Chang Won Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, KoreaType 2 diabetes mellitus (T2DM) is marked by chronic hyperglycemia, gradually worsening β-cell failure, and insulin resistance. Glucotoxicity and oxidative stress cause β-cell failure by increasing reactive oxygen species (ROS) production, impairing insulin secretion, and disrupting transcription factors such as pancreatic and duodenal homeobox 1 (PDX-1) and musculoaponeurotic fibrosarcoma oncogene family A (MafA). Cluster determinant 36 (CD36), an essential glycoprotein responsible for fatty acid uptake, exacerbates oxidative stress and induces the apoptosis of β-cells under hyperglycemic conditions through pathways involving ceramide, thioredoxin-interacting protein (TXNIP), and Rac1-nicotinamide adenine dinucleotide phosphate oxidase (NOX)-mediated redoxosome formation. Targeting CD36 pathways has emerged as a promising therapeutic strategy. Oral hypoglycemic agents, such as metformin, teneligliptin, and pioglitazone, have shown protective effects on β-cells by enhancing antioxidant defenses. These agents reduce glucotoxicity via mechanisms such as suppressing CD36 expression and stabilizing mitochondrial function. Additionally, novel insights into the glutathione antioxidant system and its role in β-cell survival underscore its therapeutic potential. This review focuses on the key contribution of oxidative stress and CD36 to β-cell impairment, the therapeutic promise of antioxidants, and the need for further research to apply these findings in clinical practice. Promising strategies targeting these mechanisms may help preserve β-cell function and slow T2DM progression.http://e-dmj.org/upload/pdf/dmj-2024-0796.pdfcd36 antigensdiabetes mellitus, type 2hyperglycemiainsulin-secreting cellsoxidative stressreactive oxygen species
spellingShingle Il Rae Park
Yong Geun Chung
Kyu Chang Won
Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
Diabetes & Metabolism Journal
cd36 antigens
diabetes mellitus, type 2
hyperglycemia
insulin-secreting cells
oxidative stress
reactive oxygen species
title Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
title_full Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
title_fullStr Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
title_full_unstemmed Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
title_short Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
title_sort overcoming β cell dysfunction in type 2 diabetes mellitus cd36 inhibition and antioxidant system
topic cd36 antigens
diabetes mellitus, type 2
hyperglycemia
insulin-secreting cells
oxidative stress
reactive oxygen species
url http://e-dmj.org/upload/pdf/dmj-2024-0796.pdf
work_keys_str_mv AT ilraepark overcomingbcelldysfunctionintype2diabetesmellituscd36inhibitionandantioxidantsystem
AT yonggeunchung overcomingbcelldysfunctionintype2diabetesmellituscd36inhibitionandantioxidantsystem
AT kyuchangwon overcomingbcelldysfunctionintype2diabetesmellituscd36inhibitionandantioxidantsystem